A Chinese biotech company has claimed that a new anti-aging pill could help humans live up to 150 years, but the idea remains unproven in humans.
Shenzhen-based Lonvi Biosciences is developing a capsule based on Procyanidin C1, also known as PCC1. The compound is found in grape seed extract and has drawn attention for its possible anti-aging effects.
The company claims the pill targets senescent cells, which are also known as “zombie cells.” These are old or damaged cells that stop dividing but remain in the body. Over time, they can contribute to inflammation and age-related health problems.
According to reports, Lonvi Biosciences believes PCC1 could become part of a wider approach to slowing aging and improving health in later life. The company has also suggested that living up to 150 years could become realistic in the future.
However, scientists have not yet proven that the pill can extend human life to that level.
The main research behind PCC1 comes from animal studies. A 2021 study published in Nature Metabolism found that PCC1 improved health and increased lifespan in mice by acting on senescent cells.
Still, results in mice do not always translate to humans. Researchers would need large and carefully controlled human trials before making any reliable claims about longer human life.
Experts have also urged caution because the current evidence is still limited. While PCC1 may be a promising area of longevity research, there is no verified clinical proof that it can help people live to 150 years.
The growing interest in the pill also reflects China’s wider push into biotechnology and longevity science. Several companies around the world are now studying treatments that target aging-related processes instead of only treating individual diseases.
For now, the pill remains an experimental longevity product, not a proven life-extension treatment. Human studies will determine whether the company’s claims can stand up to scientific review.